Research Studies

Division of Hematology Research Studies

Find research studies available to children cared for by the Division of Hematology team.
Contact us

Search Research Studies

Recruitment Status
Non-recruiting (3)

Related conditions
Alpha Thalassemia (1)
Anemia (1)
Beta Thalassemia (Cooley's Anemia) (1)
Hemophilia (1)

Study categories
Adults (3)
Children (1)
MRI/Imaging Studies (1)

Specialty
General Pediatrics (1)
(-) Hematology (3)

Eligible age

Clinical trial phase
Phase I (1)
(-) Phase II (3)
Phase III (3)
Phase IV (1)
N/A (1)

ENERGY Study

The ENERGY study is for adults (ages 18 and up) with warm Autoimmune Hemolytic Anemia (wAIHA) who are currently receiving treatment or have previously received treatment. The goal of the study is to see if the study drug, Nipocalimab is safe and effective in the treatment of wAIHA. Nipocalimab is an investigational medication designed to stop your immune system from destroying your red blood cells.

You may be able to join the study if you are:

  • 18 years of age or older
  • Diagnosed with wAIHA for at least 3 months
  • Currently receiving treatment or have previously received treatment for wAIHA
  • Have platelet counts of more than 30,000/ L and Hemoglobin less than 10 g/dL

Other study requirements will apply.

Phase: Phase II, Phase III

Actively recruiting: No

Category: Adults

Gene Therapy Trial for Hemophilia A
This clinical trial study uses a modified adeno-associated virus (AAV) to carry the human factor VIII gene to the liver. In the liver is where factor VIII protein is made. The study product, SPK-8011, is available only to participants in this research study. This product has not been approved yet for use in the general public. This will be the first hemophilia A gene transfer research study done in the United States. To learn more about the benefits and risks related to this study, please contact Dr. Lindsey George at (267) 425-0132.In order to participate in this study, you must be male, 18 years or older, have hemophilia A with FVIII activity levels less or equal to 2%, a history of bleeding that requires prophylaxis or on demand therapy, and no history of inhibitor to factor VIII. This study requires a number of visits over the course of 12 months. All costs related to participation in the study will either be covered or reimbursed by the Sponsor of the study, Spark Therapeutics, and participants will be compensated for their time.

Phase: Phase I, Phase II

Actively recruiting: No

Category: Adults, MRI/Imaging Studies

Conditions: Hemophilia

Gladiolus Study

This Phase 2 clinical research study is evaluating the safety and effectiveness of a once-daily oral investigational medicine that may improve anemia and reduce the need for red blood cell (RBC) transfusions among some patients who are chronically transfused. All participants enrolled in the study will receive the investigational medication.

We are currently enrolling individuals who meet the following criteria:*

  • Regular RBC transfusions to prevent stroke or recurrence of stroke (Cohort A)
  • Thalassemia and receiving regular RBC transfusions (Cohort B)
  • Thalassemia and not receiving regular RBC transfusions (Cohort C)

There are additional eligibility requirements, which the investigator will explain to you.

Phase: Phase II

Actively recruiting: No

Category: Adults, Children

Conditions: Alpha Thalassemia, Beta Thalassemia (Cooley's Anemia), Anemia